Wright & Schulte Continues To Investigate Xarelto Lawsuits Claims Alleging Bayer Healthcare And Janssen Pharmaceuticals Inc. Failed To Disclose The Bleeding Side-Effect Risk Of The Blood-Thinner Xarelto.
As pretrial proceedings move forward in state and federal courts for Xarelto complaints, Wright & Schulte LLC comments that Xarelto bleeding lawsuits continue to be filed over the blood thinner medication and indicating a personal injury lawsuit was recently filed on behalf of a California woman who died after suffering from a brain bleed allegedly as a result of using Xarelto. The complaint said the woman was prescribed Xarelto in August 2012 to treat atrial fibrillation and in October 2014, she experienced a hemorrhagic bleeding on the brain and died as a result. The Xarelto bleeding lawsuit accuses Xarelto manufacturer, Bayer Healthcare, and Janssen Pharmaceuticals Inc., a subsidiary of Johnson & Johnson, of failing to warn physicians and their patients about the blood thinner’s bleeding risks and that Xarelto does not have an antidote to reverse the medication’s effects. The lawsuit was filed on January 15 in the U.S. District Court, Southern District of California. (3:15-cv-00084)
Wright & Schulte LLC continues to speak with men and women across the country who believe they have experienced bleeding side-effects due to the prescription blood thinner Xarelto. The firm offers free legal consultations to those who believe they have suffered uncontrollable bleeding, hemorrhaging and other side-effects as a result of using Xarelto and other prescription blood thinners. The firms experienced attorneys are available to help answer your questions by calling 1-800-399-0795 or you can visit yourlegalhelp.com for more information on this and other prescription drug lawsuits.
Xarelto (rivaroxaban) was approved by the U.S. Food & Drug Administration (FDA) to prevent deep vein thrombosis, pulmonary embolism and to reduce the risk of stroke in people with atrial fibrillation. The oral anticoagulant is considered a new generation blood thinner when compared to warfarin, a blood thinner approved by the FDA in 1954. Until newer blood thinners like Xarelto, Pradaxa and Eliquis received FDA approval, warfarin had been the only FDA-approved blood thinner on the market used to prevent strokes in patients with atrial fibrillation. According to the FDA, warfarin must be carefully monitored with periodic blood tests while the newer anticoagulants do not need the periodic blood test monitoring. The new generation blood thinners, however, can cause bleeding and there are no antidotes to reverse the effects of the medications, the federal agency said. Warfarin uses vitamin K as an antidote to reverse the effects of bleeding.
[fda.gov/Drugs/NewsEvents/ucm405148.htm, July 17, 2014]
Xarelto Bleeding Lawsuits
Wright & Schulte LLC states that court records indicate Xarelto bleeding lawsuits that allege the blood thinner causes uncontrollable internal bleeding and other complications have been consolidated in the Philadelphia Court of Common Pleas. Administrative Judge Kevin Dougherty created a mass tort program in January for all Xarelto lawsuits filed in the state of Pennsylvania. Judge Dougherty issued a Case Management Order in January that granted a plaintiff’s request to centralize all Xarelto lawsuits in the court’s Complex Litigation Center for coordinated pretrial proceedings. Judge Dougherty transferred 75 Xarelto lawsuits into the litigation program at the time he issued his order on January 20. There are 97 Xarelto bleeding complaints pending as of February 9. “Consolidating Xarelto bleeding lawsuits allows for a more cohesive litigation” – Wright & Schulte LLC. (In Re: Xarelto Litigation, Case Number 150102349)
In December, the U.S. Judicial Panel on Multidistrict Litigation (JPML) transferred 21 Xarelto bleeding complaints filed in federal courts nationwide to the U.S. District Court, Eastern District of Louisiana. The federally filed Xarelto complaints were coordinated in the Louisiana district court to avoid duplication of discovery and to prevent inconsistent pretrial rulings, among other things. According to the JPML, the federal Xarelto cases have common allegations that the defendants failed to warn doctors about the bleeding risks associated with the blood thinner and the medication has no reversal agent should severe bleeding occur in the patient. There are 86 Xarelto lawsuits pending in the multidistrict litigation as of January 15, according to the JPML’s list of pending MDL dockets. (In re: Xarelto (Rivaroxaban) Products Liability Litigation, MDL 2592)
About Wright & Schulte LLC
Wright & Schulte LLC, an experienced personal injury firm, is dedicated to the belief that America’s legal system should work for the people. Every day, the attorneys of Wright & Schulte LLC stand up for the rights of people who have been injured or wronged and fight tirelessly to ensure that even the world’s most powerful corporations take responsibility for their actions. If you’re looking for a law firm that will guarantee the aggressive and personal representation you deserve, please do not hesitate to contact Wright & Schulte LLC today. Free Xarelto bleeding lawsuit case evaluations are available through yourlegalhelp.com or by calling 1-800-399-0795.
Wright & Schulte LLC
865 S. Dixie Dr.
Vandalia, Ohio 45377